NDC Pharmacologic Class N0000191622 Poly(ADP-Ribose) Polymerase Inhibitors [MoA]

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Product Type
0069-0296Talzenna TalazoparibCapsuleOralPfizer Laboratories Div Pfizer IncHuman Prescription Drug
0069-1195Talzenna TalazoparibCapsuleOralPfizer Laboratories Div Pfizer IncHuman Prescription Drug
0310-0657Lynparza OlaparibCapsuleOralAstrazeneca Pharmaceuticals LpHuman Prescription Drug
0310-0668Lynparza OlaparibTablet, Film CoatedOralAstrazeneca Pharmaceuticals LpHuman Prescription Drug
0310-0679Lynparza OlaparibTablet, Film CoatedOralAstrazeneca Pharmaceuticals LpHuman Prescription Drug
63539-295Talzenna TalazoparibCapsuleOralU.s. PharmaceuticalsHuman Prescription Drug
69656-103Zejula NiraparibCapsuleOralTesaro, Inc.Human Prescription Drug
69660-201Rubraca RucaparibTablet, Film CoatedOralClovis Oncology, Inc.Human Prescription Drug
69660-202Rubraca RucaparibTablet, Film CoatedOralClovis Oncology, Inc.Human Prescription Drug
69660-203Rubraca RucaparibTablet, Film CoatedOralClovis Oncology, Inc.Human Prescription Drug

There are 10 NDC products with the pharmacologic class Poly(ADP-Ribose) Polymerase Inhibitors [MoA].